Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aquestive Therapeutics ( (AQST) ) has shared an announcement.
On May 12, 2026, Aquestive Therapeutics entered into a new five‑year term loan facility of up to $150 million with funds managed by Oaktree, including a $55 million tranche funded at closing to refinance $45 million of existing debt without penalties, and additional tranches tied to future FDA approval and sales milestones for Anaphylm. The facility, secured by substantially all company assets and structured with interest‑only payments until 2031, tightens liquidity and net sales covenants but lowers near‑term principal obligations, and is complemented by equity‑linked warrants for Oaktree that modestly increase potential dilution while extending Aquestive’s cash runway to support the planned Anaphylm launch and broader AdrenaVerse pipeline.
In parallel, Aquestive reported first‑quarter 2026 results on May 13, 2026, highlighted by completion of a Type A FDA meeting that keeps it on track to resubmit the Anaphylm NDA in the third quarter of 2026 and supports global filings using existing data. The company also advanced its AQST‑108 topical gel program with clean phase 1 safety data and a promising biomarker signal, expanded its planned Anaphylm sales force by 50% to about 75 representatives, and reaffirmed stable manufacturing volumes for partnered oral film products, underscoring a strategy to balance near‑term commercialization investments with strengthened funding capacity.
The most recent analyst rating on (AQST) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
The score is held down primarily by weak financial performance (widening losses, negative gross profit, ongoing cash burn, and negative equity). Earnings-call updates provide partial support via a clearer regulatory timeline and financing/cash position, while technicals are neutral and valuation remains pressured by unprofitability and no dividend.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc., based in Warren, N.J., is a pharmaceutical company focused on advancing medicines through proprietary delivery technologies, including sublingual films and other novel dosage forms. The company develops and manufactures products for its own pipeline and for partners, targeting areas such as Type I allergic reactions, central nervous system disorders, and dermatologic conditions.
Its commercial manufacturing business remains steady, producing oral film products like Suboxone for Indivior, Sympazan for Cosette in the U.S., Ondif for Hypera in Brazil, and Emylif for Zambon in Europe. Aquestive also operates its AdrenaVerse epinephrine prodrug platform and is positioning Anaphylm, a needle‑free epinephrine sublingual film, as a potential first‑in‑class treatment for anaphylaxis, alongside AQST‑108 for dermatologic indications.
Average Trading Volume: 1,655,239
Technical Sentiment Signal: Sell
Current Market Cap: $517M
For a thorough assessment of AQST stock, go to TipRanks’ Stock Analysis page.